Evidence-based guideline: Premature Ovarian Insufficiency

被引:14
作者
Panay, Nick [1 ]
Anderson, Richard A. [2 ]
Bennie, Amy [3 ]
Cedars, Marcelle [4 ]
Davies, Melanie [5 ]
Ee, Carolyn [6 ]
Gravholt, Claus H. [7 ]
Kalantaridou, Sophia [8 ]
Kallen, Amanda [9 ,10 ]
Kim, Kimberly Q. [11 ]
Misrahi, Micheline [12 ]
Mousa, Aya [13 ]
Nappi, Rossella E. [14 ,15 ]
Rocca, Walter A. [16 ]
Ruan, Xiangyan [17 ]
Teede, Helena [13 ]
Vermeulen, Nathalie [18 ]
Vogt, Elinor [19 ]
Vincent, Amanda J. [13 ]
机构
[1] Imperial Coll London, Queen Charlottes & Chelsea Hosp, London, England
[2] Univ Edinburgh, Inst Regenerat & Repair, Ctr Reprod Hlth, Edinburgh, Scotland
[3] E Suffolk Hosp, Suffolk, England
[4] Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA
[5] Univ Coll London Hosp, Reprod Med Unit, London, England
[6] Western Sydney Univ, NICM Hlth Res Inst, Penrith, NSW, Australia
[7] Aarhus Univ Hosp, Dept Endocrinol, Aarhus, Denmark
[8] Natl & Kapodistrian Univ Athens, Dept Obstet & Gynecol 3, Athens, Greece
[9] Univ Vermont, Larner Coll Med, Div Reprod Endocrinol & Infertil, Burlington, VT USA
[10] Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
[11] RESOLVE Natl Infertil Assoc, Mclean, VA USA
[12] Univ Paris Saclay, Hop Bicetre, Fac Med, Le Kremlin Bicetre, France
[13] Monash Univ, Monash Ctr Hlth Res & Implementat MCHRI, Clayton, Australia
[14] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy
[15] IRCCS San Matteo Fdn, Res Ctr Reprod Med Gynecol Endocrinol & Menopause, Pavia, Italy
[16] Mayo Clin, Dept Neurol, Rochester, MN USA
[17] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing, Peoples R China
[18] ESHRE Cent Off, Strombeek Bever, Belgium
[19] Haukeland Hosp, Dept Med, Bergen, Norway
关键词
premature ovarian insufficiency; primary ovarian insufficiency; hormone therapy; hormone replacement therapy; combined oral contraceptive; puberty induction; fertility; bone; brain; cardiovascular;
D O I
10.1016/j.fertnstert.2024.11.007
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Study Question: How should premature/primary ovarian insufficiency (POI) be diagnosed and managed, based on the best available evidence from published literature? Summary Answer: The current guideline provides 145 recommendations on symptoms, diagnosis, causation, sequelae and treatment of POI. What is Known Already: Premature ovarian insufficiency (POI) presents a significant challenge to women's health, with far-reaching implications, both physically and emotionally. The potential implications include adverse effects on quality of life; fertility; and bone, cardiovascular and cognitive health. Although hormone therapy (HT) can mitigate some of these effects, many questions still remain regarding the optimal management of POI. Study Design, Size, Duration: The guideline was developed according to the structured methodology for development of ESHRE guidelines. Key questions were determined by a group of experts and informed by a scoping survey of women and health care professionals. Literature searches and assessment were then performed. Papers published up to January 30th, 2024, and written in English were included in the guideline. An integrity review was conducted for the randomised controlled trials (RCTs) on POI included in the guideline. Participants/Materials, Setting, Methods: Based on the collected evidence, recommendations were formulated and discussed within the guideline development group until consensus was reached. Women with lived experience of POI informed the recommendations in general, and particularly on those on provision of care. A stakeholder review was organised after finalisation of the draft. The final version was approved by the guideline development group and the ESHRE Executive Committee. Main Results and The Role of Chance: New data indicate a higher prevalence of POI, 3.5%, than was previously thought. This guideline aims to help health care professionals to apply best practice care for women with POI. The recent update of the POI guideline covers 40 clinical questions on diagnosis of the condition, the different sequelae, including bone, cardiovascular, neurological and sexual function, fertility and general well-being, and treatment options, including hormone therapy. The list of clinical questions was expanded from the previous iteration of the guideline (2015) based on the scoping survey and appreciation of emerging knowledge of POI.
引用
收藏
页码:221 / 236
页数:16
相关论文
共 6 条
[1]   Global Consensus Position Statement on the Use of Testosterone Therapy for Women [J].
Davis, Susan R. ;
Baber, Rodney ;
Panay, Nicholas ;
Bitzer, Johannes ;
Cerdas Perez, Sonia ;
Islam, Rakibul M. ;
Kaunitz, Andrew M. ;
Kingsberg, Sheryl A. ;
Lambrinoudaki, Irene ;
Liu, James ;
Parish, Sharon J. ;
Pinkerton, JoAnn ;
Rymer, Janice ;
Simon, James A. ;
Vignozzi, Linda ;
Wierman, Margaret E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (10) :4660-4666
[2]   The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis [J].
Golezar, S. ;
Tehrani, F. Ramezani ;
Khazaei, S. ;
Ebadi, A. ;
Keshavarz, Z. .
CLIMACTERIC, 2019, 22 (04) :403-411
[3]   The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis [J].
Li, M. ;
Zhu, Y. ;
Wei, J. ;
Chen, L. ;
Chen, S. ;
Lai, D. .
CLIMACTERIC, 2023, 26 (02) :95-102
[4]   Research Integrity in Guidelines and evIDence synthesis (RIGID): a framework for assessing research integrity in guideline development and evidence synthesis [J].
Mousa, Aya ;
Flanagan, Madeline ;
Tay, Chau Thien ;
Norman, Robert J. ;
Costello, Michael ;
Li, Wentao ;
Wang, Rui ;
Teede, Helena ;
Mol, Ben W. .
ECLINICALMEDICINE, 2024, 74
[5]  
Vermeulen N, 2020, Manual for ESHRE guideline development
[6]  
Webber L, 2016, HUM REPROD, V31, P926, DOI [10.18370/2309-4117.2017.37.41-48, 10.1093/humrep/dew027]